112905-94-9

Upstream product

• 6714-68-7 spiro[1,3-dioxolane-2,3'-indolin]-2'-one 
• 139017-66-6 1-<<1'-<2'(1'H)-oxospiro<1,3-dioxolane-2,3'-indol>yl>>-methyl>cyclohexanecarbonitrile 
• 112905-96-1 2',3',4',10'-tetrahydro-1,3-dioxolane-2-spiro-10'-pyrimido<1,2-a>indole-3'-spirocyclohexane 
• 112905-97-2 3',4'-dihydrospiroindol>-10'(2'H)-one 
• 91-56-5 indole-2,3-dione 
• 112905-88-1 2',3',4',10'-Tetrahydro-10'-hydroxy-10'-phenylspiro [cyclohexane-1,3'-pyrimido(1,2-a)indole] 

Downstream Products

• 112905-93-8 C₂₂H₂₄N₂O 

Relevant academic research and scientific papers

Oral Hypoglycemic Agents. Pyrimidoindoles and Related Compounds

A series of pyrimidoindoles were synthesized and studied for their hypoglycemic activity following oral administration at standard dose of 100 mg/kg to fed rats.The effect of 10-alkoxyalkyl, 10-alkyl, 10-aryl, and 3,3-dialkyl substitution on the activity of 10-hydroxypyrimidoindoles was investigated.Relative potencies of a number of the most active compounds were defined by three-point dose-response studies.The most potent compounds were those with either 3,3-dimethyl substituents, compounds 21, 22, and 38, or 3,3-spirocyclohexane substituents, compounds 39 and 49. 10-Aminopyrimidoindoles were in general less active than the 10-hydroxy analogues, and potency was further decreased by derivatizing the 10-amino group.The most potent 10-amino derivatives were 57 and 58.

Hypoglycemic 2',3',10'-tetrahydro-10'-hydroxy-10'-substituted-spiro[cycloakane-1,3'-pyrimido(1,2-a)indole]deratives

Pyrimidoindoles of formula (I) STR1 and their pharmaceutically acceptable acid addition salts, wherein R represents lower alkyl a mono- or bicyclic aryl radical or a group of mormula R3 O--B--[where R3 O is (lower)alkoxy,aryl(lower)a